SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.

Shenzhen Salubris Pharmaceuticals Co., Ltd.

002294

CNE100000FW8

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
29.97 ^CNY	-1.90%		+3.67%	-8.24%

Apr. 23	Salubris Pharmaceuticals' Q1 Profit Falls 5% Despite 23% Rise in Operating Income	MT
Apr. 23	Salubris Pharmaceuticals to Raise Capital of US Unit by $35 Million	MT

Shenzhen Salubris Pharmaceuticals Co., Ltd. authorizes a Buyback Plan.

October 05, 2019

The Board of Directors of Shenzhen Salubris Pharmaceuticals Co., Ltd. has authorized a buyback plan on October 6, 2019.

Latest news about Shenzhen Salubris Pharmaceuticals Co., Ltd.

Salubris Pharmaceuticals' Q1 Profit Falls 5% Despite 23% Rise in Operating Income	Apr. 23	MT
Salubris Pharmaceuticals to Raise Capital of US Unit by $35 Million	Apr. 22	MT
Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 22	CI
Shenzhen Xintai Pharmaceutical's Drug to Treat Chronic Heart Failure Set for Clinical Trials	Apr. 08	MT
Salubris Pharma's Profit, Revenue Slip in 2023	Mar. 26	MT
Shenzhen Salubris Pharmaceuticals Co., Ltd. Proposes Final Cash Dividend for the Year 2023	Mar. 25	CI
Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Salubris Pharmaceuticals Gets Nod to Trial SAL0120 Tablets	23-10-09	MT
Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Salubris Pharmaceuticals Gets US FDA Nod for Arthritis Drug Trial	23-07-18	MT
Precision Scientific announced that it has received funding from Shenzhen Salubris Pharmaceuticals Co., Ltd.	23-06-25	CI
Salubris Pharma Gets Nod for Kidney Disease Tablets	23-06-12	MT
Shenzhen Salubris Pharmaceuticals Co., Ltd. Approves Final Cash Dividend for A Shares for the Year 2022	23-04-27	CI
Shenzhen Salubris Pharmaceuticals Co., Ltd. Approves Final Cash Dividend for 2022	23-04-19	CI
Salubris Pharmaceuticals' 2022 Adjusted Profit Down 11%	23-04-19	MT
Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-18	CI
Shenzhen Salubris Pharmaceuticals Co., Ltd. Proposes Final Dividend for the Year 2022	23-03-28	CI
Salubris Pharmaceuticals Plans to Spin Off Medical Instrument Unit for Listing	23-03-28	CI
Shenzhen Salubris Pharmaceuticals Co., Ltd. agreed to Spin-Off Medical Instrument Unit of Shenzhen Salubris Pharmaceuticals Co Ltd.	23-03-27	CI
Salubris Pharmaceutical Co., Ltd. announced that it expects to receive CNY 26 million in funding from Shenzhen Salubris Pharmaceuticals Co., Ltd.	23-01-17	CI
Salubris Pharmaceuticals to Begin Clinical Trial of Anti-COVID-19 Tablets	23-01-04	MT
Kexing Enrols Subjects in Phase II Clinical Trial of Oral COVID-19 Drug	23-01-03	MT
Shenzhen Salubris Pharmaceuticals Gets Nod for Anti-Tumor Drug Trial	22-12-30	MT
Shenzhen Salubris Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-24	CI

Chart Shenzhen Salubris Pharmaceuticals Co., Ltd.

Duration

Period

Chart Shenzhen Salubris Pharmaceuticals Co., Ltd.

More charts

SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. is a China-based company, principally engaged in the research and development, manufacture and distribution of pharmaceuticals. The Company provides two categories of products: pharmaceutical preparation and bulk drugs. The Company is also engaged in the research and development, production and sales of cardiovascular medical devices. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-27 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Shenzhen Salubris Pharmaceuticals Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

29.97 CNY

Average target price

37 CNY

Spread / Average Target

+23.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-8.24%	4.6B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.35%	42.77B
OTSUKA HOLDINGS CO., LTD.	+19.85%	22.23B
SANDOZ GROUP AG	+13.12%	14.44B
CIPLA LIMITED	+11.96%	13.05B
ZYDUS LIFESCIENCES LIMITED	+35.67%	11.59B
ONO PHARMACEUTICAL CO., LTD.	-9.04%	6.95B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+6.29%	4.97B

Generic Pharmaceuticals